Cambios en la densidad de masa ósea en mujeres con cáncer de mama precoz que han recibido quimioterapia adyuvante con y sin bifosfonatos
- Alonso Álvarez, Beatriz
- Alemán Valls, María Remedios
- Rodríguez Rodríguez, Milva
- Llanos Muñoz, Marta
- González Reimers, Carlos Emilio
- Batista López, N.
ISSN: 0423-4804
Ano de publicación: 2008
Número: 52
Páxinas: 137-148
Tipo: Artigo
Outras publicacións en: Estudios Canarios: Anuario del Instituto de Estudios Canarios
Resumo
Adjuvant therapies have prolonged survival of non-metastatic breast cancer (NMBC) patients, but they also decrease bone mineral density (BMD). There is increased interest in the potencial role of bisphosphonate drugs in preventing and treating chemotherapy-induced bone loss. We have analyzed the effects of chemotherapy on BMD of women with NMBC who received before first cycle intravenous zoledronic acid. We prospectively included 88 women with NMBC (stage I-III) referred to the Medica! Oncology Service of University Hospital of Canary Islands. We measured lumbar and hip BMD at diagnosis, and after chemotherapy. BMD after chemotherapy significantly increased trochanter and femoral neck areas, and remained stable lumbar, total hip, intertrochanter, and Ward' s triangle areas. Intravenous bisphosphonate (zoledronic acid) in our study have demostrate a benefit in reducing the loss bone mineral density after chemotherapy in women with NMBC